All In Biotech

Drug Trial Radar · NCT05433285

Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Immunogenicity & Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Bio Farma) Adjuvanted With Alum+CpG 1018 Compared to Registered Covid-19 Vaccine (Covovax - Protein Subunit Vaccine) in Healthy Populations Aged 18 Years and Above in Indonesia (Phase III)

Last checked: Nov 20, 2026Latest source record: Nov 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,050 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,050

Actual

Start

Jun 7, 2022

Primary completion

Aug 5, 2022

Study completion Aug 31, 2023

Sponsor

Lead sponsor
PT Bio FarmaIndustry
Sponsor type
Industry
Collaborators
Fakultas Kedokteran Universitas Indonesia; Faculty of Medicine Universitas Diponegoro; Andalas University; Faculty of Medicine Universitas Hassanudin
First posted
Jun 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Observer-blind, randomized, active-controlled prospective intervention study

Conditions

  • COVID-19

Interventions

  • COVID-19 Protein Subunit Recombinant VaccineBiological

    SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

  • Active ComparatorBiological

    Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immunogenicity of the candidate vaccineTime frame: 14 days after the last dose
  2. Seroconversion rate of the candidate vaccineTime frame: 14 days after the last dose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Faculty of Medicine Diponegoro University

    Semarang, Central Java, Indonesia

  • Fakultas Kedokteran Universitas Indonesia

    Jakarta, Greater Jakarta, Indonesia

  • Faculty of Medicine Universitas Hassanudin

    Makassar, South Sulawesi, Indonesia

  • Faculty of Medicine Universitas Andalas

    Padang, West Sumatera, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.